A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Degarelix (Primary) ; Gonadotropin releasing hormone stimulants
- Indications Prostate cancer
- Focus Pharmacodynamics
- 13 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
- 13 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2018.
- 13 Jul 2017 Status changed from recruiting to active, no longer recruiting.